Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, and commercial organizations in the United States. The company operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, federal, and corporate management services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Financial Resilience | Centene's conservative 2025 guidance, projecting EPS over $7.25, may understate its true potential, with analysts foreseeing 15% annual EPS growth through 2027 |
Medicaid Dynamics | Explore Centene's cautious approach to Medicaid rates and MLR, potentially setting the stage for positive surprises if rates improve faster than anticipated |
Market Positioning | Delve into Centene's strategy for navigating the Marketplace shift and strengthening its position in the growing dual eligibles market |
Regulatory Landscape | Learn how Centene is addressing challenges such as subsidy expirations and Medicaid expansion, while maintaining a $90-$97 average price target range |
Metrics to compare | CNC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCNCPeersSector | |
---|---|---|---|---|
P/E Ratio | 8.6x | 18.3x | −0.5x | |
PEG Ratio | 0.33 | −0.20 | 0.00 | |
Price/Book | 1.1x | 2.0x | 2.6x | |
Price / LTM Sales | 0.2x | 1.0x | 2.9x | |
Upside (Analyst Target) | 30.5% | 19.2% | 58.9% | |
Fair Value Upside | Unlock | −2.1% | 8.0% | Unlock |